Testing effectiveness (Phase 2)Ended earlyNCT01251965What this trial is testingPhase l/II Study of Ruxolitinib for Acute LeukemiaWho this might be right forLeukemia M.D. Anderson Cancer Center 27
Early research (Phase 1)Ended earlyNCT04553692What this trial is testingPhase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed CancersWho this might be right forSolid TumorColorectal CancerNon Hodgkin Lymphoma+5 more IGM Biosciences, Inc. 272
Early research (Phase 1)Looking for participantsNCT03326921What this trial is testingHA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell TransplantWho this might be right forJuvenile Myelomonocytic LeukemiaRecurrent Acute Biphenotypic LeukemiaRecurrent Acute Undifferentiated Leukemia+26 more Fred Hutchinson Cancer Center 24
Testing effectiveness (Phase 2)Study completedNCT00003840What this trial is testingDTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid LeukemiaWho this might be right forLeukemia Wake Forest University Health Sciences
Early research (Phase 1)Ended earlyNCT02177812What this trial is testingA Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)Who this might be right forLeukaemia, Myelocytic, Acute GlaxoSmithKline 41
Testing effectiveness (Phase 2)Study completedNCT01736943What this trial is testingBortezomib and Doxil for the Treatment of Patients With Acute Myelogenous LeukemiaWho this might be right forAcute Myelogenous Leukemia Joseph Tuscano 25
Early research (Phase 1)Study completedNCT00077558What this trial is testing3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic SyndromeWho this might be right forLeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Early research (Phase 1)Looking for participantsNCT06820268What this trial is testingXS-04 in Patients with Relapsed or Refractory Hematologic MalignanciesWho this might be right forB-cell LymphomaAcute Myeloid LeukemiaMyelodysplastic Syndrome NovaOnco Therapeutics Co., Ltd. 168
Not applicableStudy completedNCT00310115What this trial is testingMotivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During PregnancyWho this might be right forBladder CancerCervical CancerEsophageal Cancer+8 more M.D. Anderson Cancer Center 469
Early research (Phase 1)Study completedNCT00036790What this trial is testingMotexafin Gadolinium and Doxorubicin in Treating Patients With Advanced CancerWho this might be right forBreast CancerChronic Myeloproliferative DisordersColorectal Cancer+9 more University of Wisconsin, Madison
Not applicableStudy completedNCT00996047What this trial is testingS9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic CancersWho this might be right forLeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms SWOG Cancer Research Network 3,341
Early research (Phase 1)Active Not RecruitingNCT03766126What this trial is testingLentivirally Redirected CD123 Autologous T Cells in AMLWho this might be right forAcute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, AdultAcute Myeloid Leukemia, Refractory University of Pennsylvania 22
Early research (Phase 1)Ended earlyNCT02353143What this trial is testingStudy of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid LeukemiaWho this might be right forRecurrent Adult Acute Myeloid LeukemiaAcute Myeloid Leukemia, in Relapse Menarini Group 71
Testing effectiveness (Phase 2)Study completedNCT00569010What this trial is testingPhase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)Who this might be right forAcute Myelogenous LeukemiaMyelodysplastic SyndromeLeukemia M.D. Anderson Cancer Center 36
Testing effectiveness (Phase 2)Study completedNCT01789255What this trial is testingVorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological MalignanciesWho this might be right forAccelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities+115 more National Cancer Institute (NCI) 12
Not applicableStudy completedNCT00053157What this trial is testingSargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic AnemiaWho this might be right forChronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+3 more Roswell Park Cancer Institute 10
Testing effectiveness (Phase 2)Study completedNCT00309907What this trial is testingEtanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell TransplantWho this might be right forAccelerated Phase Chronic Myelogenous LeukemiaBlastic Phase Chronic Myelogenous LeukemiaChildhood Acute Lymphoblastic Leukemia in Remission+22 more Children's Oncology Group 39
Early research (Phase 1)Looking for participantsNCT06950034What this trial is testingSTX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)Who this might be right forChronic Myelomonocytic LeukemiaChronic Myelomonocytic Leukemia (CMML)Chronic Myelomonocytic Leukemia-1+9 more Solu Therapeutics, Inc 105
Testing effectiveness (Phase 2)Study completedNCT00233909What this trial is testingA Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid LeukemiaWho this might be right forLeukemia, Myeloid Kanisa Pharmaceuticals 55
Early research (Phase 1)Looking for participantsNCT07263906What this trial is testingClinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid LeukemiaWho this might be right forRefractory Acute Myeloid LeukemiaRecurrent Acute Myeloid Leukemia Second Affiliated Hospital, School of Medicine, Zhejiang University 48